Most of the mutations identified in secondary MDS and AML belong to the DNA damage response (DDR) pathway, such as PPM1D and TP53, with the latter being common in high-grade serous ovarian carcinoma, occurring in up to 96% of cases.18 This evidence concerns the gene TP53 and myelodysplastic syndrome.